Our previous work showed that Zbed3 is overexpressed in nonsmall cell lung cancer and that down-regulation of Zbed3 inhibited β-catenin expression and cancer cell proliferation and invasiveness. Here, we investigated Zbed3's ability to promote lung cancer cell proliferation and invasion and the involvement of the Axin/ TPC/glycogen synthase kinase 3β (Gsk-3β) complex to the response. Coimmunoprecipitation assays showed that wild-type Zbed3 bound to Axin but a Zbed3 mutant lacking the Axin binding site did not. In A549 and H1299 lung cancer cells, Zbed3 overexpression promoted cancer cell proliferation and invasiveness, as well as Wnt signalling and expression of downstream mediators, including β-catenin, cyclin D1 and MMP7 (P < 0.05). In contrast, the Zbed3 mutant failed to enhance β-catenin expression (P > 0.05), and its ability to promote cancer cell proliferation and invasiveness was much less than wild-type Zbed3 (P < 0.05). The ability of Zbed3 to increase β-catenin levels was abolished by Axin knockdown in A549 cells (P > 0.05). Similarly, treating the cells with a GSK-3β inhibitor abolished Zbed3's ability to increase β-catenin levels and Wnt signalling. These results indicate that Zbed3 enhances lung cancer cell proliferation and invasiveness at least in part by inhibiting Axin/adenomatous polyposis coli/GSK-3β-mediated negative regulation of β-catenin levels.
| INTRODUCTION
Abnormal Wnt signalling contributes to the development and progression of many malignancies. [1] [2] [3] [4] β-catenin is a key mediator of Wnt signalling that is degraded via a complex composed of Axin, adenomatous polyposis coli (APC), and serin/threonine glycogen synthase kinase 3β
(GSK-3β) when Wnt signalling is not activated. 5, 6 When activated, Wnt signalling activates Disheveled, which in turn inhibits phosphorylation of β-catenin by the Axin/APC/GSK-3β complex and prevents its degradation via the ubiquitin proteasome. β-catenin is accumulated in cytoplasm and then translocated to the nucleus, where it binds to and activates transcription factor T-cell factor/Lymphoid, enhancer, factor, thereby regulating expression of target genes. 5, 6 Zbed3 belongs to the family of BED-zinc finger proteins. At present, it is predicted that there are about 2000 BED-zinc finger proteins in the creature, but most of them have not been verified at the protein level, and the related research is still in an initial stage. We previously observed that Zbed3 is overexpressed in nonsmall cell lung cancer (NSCLC) and acts as a positive regulator of β-catenin to promote NSCLC malignancy.
expression or function is seen in various cancers and is considered to be a potential therapeutic target. 8, 9 In NIH3T3 cells, Zbed3
reportedly suppresses β-catenin degradation by inhibiting the activity of the Axin/APC/GSK-3β complex. 10 Although the mechanism involved is not fully understood, it is known that Zbed3 binding to
Axin is important for inhibition of β-catenin phosphorylation by the complex. 10 To better understand the molecular mechanism of action of Zbed3 in NSCLC, in the present study we investigated the effects of Zbed3 on β-catenin expression and the proliferation and invasiveness of NSCLC cells.
| MATERIALS AND METHODS

| Cell culture and transfection
The A549 and NCI-H1299 human lung carcinoma cell lines were cultured as described previously. 7 
| Western blotting
Western blotting was performed as described previously. 7 The primary antibodies used included anti-Zbed3 (ab106383, 1:300; Abcam, HK), anti-Axin (ab56475, 1:500; Abcam), anti-β-catenin (D10A8, 1:1000; Cell Signaling, USA), anti-phospho-β-catenin (Ser33/37/ Thr41; #9561, 1:1000; Cell Signaling), anti-cyclin D1 (sc-20044, 1:200; Santa Cruz), anti-GSK-3β (E-11, sc-377213, 1:500; Santa Cruz), and anti-GADPH (ab8245, 1:1000; Abcam).
| Immunoprecipitation
Immunoprecipitation assays were performed as described previously. 11 Antibodies were added to 200 mg of proteins and gently rotated overnight at 4°C. Twenty-five millilitres of protein A/G agarose beads (Beyotime, Jiangsu, China) was added to the immunocomplex and lightly rotated for 3 hours at 4°C. The mixture was then centrifuged at 1500 g for 5 minutes at 4°C, and the supernatant was removed. The precipitate was resuspended in a sample buffer after washing three times using ice-cold radioimmunoprecipitation assay buffer, and then boiled for 5 minutes. The sample was centrifugated and the supernatant was collected to be examined by Western blotting.
| Matrigel invasion
To investigate the invasiveness of cancer cells, Transwell assays were performed using polycarbonate membrane inserts (Corning, NY, USA) and Matrigel (BD Bioscience) as described previously. 
| Colony formation
To investigate lung cancer cell proliferation, colony formation assays were performed as described previously. 7 One thousand cells were planted into 6-cm cell culture dishes after transfection for 48 hours and incubated for 10 days. The cells were then stained with Giemsa stain.
Colonies with more than 50 cells were counted under the microscope.
Each experiment was performed at least three times independently.
| MTT assays
The MTT assays were performed as described previously. 12 Cells were transferred to 96-well plates in a medium containing 10% FBS at 4000 
| Dual-luciferase assays
Dual-luciferase assays were performed as described previously. 
| Statistical analysis
Statistical analysis was performed using the SPSS statistical software package version 22.0 (SPSS Inc., Chicago, IL, USA). In vitro experiments were performed at least three times. Differences between groups were analysed using Student's t test for densitometry measurements, Matrigel invasion assays, colony formation assays, and Zbed3's ability to increase β-catenin levels is dependent on its binding to Axin.
| Zbed3 mutation suppresses its enhancement of cancer cell proliferation and invasiveness
Colony formation and MTT assays showed that transfecting lung cancer cells with wild-type Zbed3 significantly enhanced their proliferation, but that effect was largely inhibited by transfection of the Zbed3 mutant lacking an Axin binding sited ( Figure 5A and B).
In addition, Transwell assays showed that transfection of wild-type Zbed3 significantly increased the invasiveness of cancer cells, but again that effect was largely inhibited transfection of the Zbed3 mutant ( Figure 5C ). Given that overexpression of the Zbed3 mutant promoted cancer cell proliferation and invasiveness to a small degree ( Figure 5 ), we suggest Zbed3-mediated enhancement of cancer cell proliferation and invasiveness is in large part, but not However, after Axin knockdown, Zbed3's ability to enhance β-catenin expression was abolished (Figure 7 ), indicating the effect was Axin dependent. When we then treated A549 cells with the GSK-3β inhibitor TWS119, we found that levels of phospho-β-catenin were greatly suppressed, and the ability of Zbed3 to increase β-catenin levels was abolished ( Figure 8A ). Dual-luciferase assays showed that activity in the canonical Wnt signalling pathway in A549 cells was significantly increased by Zbed3 transfection. However, the ability of Zbed3 to promote Wnt signalling was abolished in TWS119-treated cells (Figure 8B) . These results indicate that Zbed3's ability to increase β-catenin expression and Wnt signalling activity was dependent on the activity of the Axin/APC/GSK-3β complex.
| DISCUSSION
Wnt signalling plays important roles during the development and progression of cancer, including NSCLC. [1] [2] [3] [4] [5] [6] We previously observed 5, 6 and that Zbed3 may regulate β-catenin by interacting with
Axin and inhibiting the function of Axin/APC/GSK3β complex. 10 Consistent with that finding, abnormal Axin expression or function has been seen in various malignancies, including NSCLC. 8, 9 We therefore investigated the effects of Zbed3 on β-catenin levels and cancer cell proliferation and invasiveness as it relates to Axin/APC/Gsk3β complex function.
Here, we found that Wnt signalling molecules, including Axin, 
